Figure 3.
Progression-free rate based on the original criteria assessed by the local investigator (A) and central committee radiologist (B). The progression-free survival rates were 84.0% in group Z and 90.0% in group P at 48 weeks (p=0.619) (A) and 84.0% in group Z and 90.0% in group P (p=0.609) (B). Group Z, zaltoprofen group; group P, placebo group.